Long-term safety and efficacy of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Efficacy and safety results from a Phase III, randomized controlled trial (ESTEEM 1)

Authors
Category Primary study
JournalJournal of Clinical and Aesthetic Dermatology
Year 2015
This article has no abstract
Epistemonikos ID: 49cc8dddb8484651c4248fbf9bfa574963032121
First added on: Feb 08, 2025